Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of LY3537031 in Normal and Impaired Renal Function
NCT07165015Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2025
- Primary completion
- Apr 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label trial of LY3537031 in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve and Maximum Concentration. Started Sep 2025; status: completed.
02
Drugs
LY3537031
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07165015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07165015.